Title:
LIGAND-BINDING MOLECULE HAVING ADJUSTABLE LIGAND-BINDING ACTIVITY
Document Type and Number:
WIPO Patent Application WO/2019/107384
Kind Code:
A1
Abstract:
The present invention relates to: a ligand-binding molecule, the ligand-binding activity of which is reduced by the cleavage of a cleavage site; a production method for the ligand-binding molecule; a complex formed of the ligand-binding molecule and a ligand; a fusion protein including the ligand-binding molecule and a ligand; and a pharmaceutical composition including the ligand-binding molecule, or a fusion protein of the ligand-binding molecule and a ligand.
More Like This:
Inventors:
IGAWA TOMOYUKI (JP)
ISHIKAWA HIROYUKI (JP)
KAWA TATSUYA (JP)
ISHIKAWA HIROYUKI (JP)
KAWA TATSUYA (JP)
Application Number:
PCT/JP2018/043692
Publication Date:
June 06, 2019
Filing Date:
November 28, 2018
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
C07K16/00; A61K38/19; A61K39/395; A61K47/68; C07K14/52; C07K19/00; C12P21/08; A61P35/00; A61P37/00; C12N15/13; C12N15/19; C12N15/62
Domestic Patent References:
| WO2004044011A2 | 2004-05-27 | |||
| WO2005040229A2 | 2005-05-06 | |||
| WO2002032925A2 | 2002-04-25 | |||
| WO1995001937A1 | 1995-01-19 | |||
| WO2002020565A2 | 2002-03-14 | |||
| WO2003029462A1 | 2003-04-10 | |||
| WO2008016854A2 | 2008-02-07 | |||
| WO2003000883A1 | 2003-01-03 | |||
| WO2004022754A1 | 2004-03-18 | |||
| WO2006006693A1 | 2006-01-19 | |||
| WO2003104453A1 | 2003-12-18 | |||
| WO2013128194A1 | 2013-09-06 | |||
| WO2010081173A2 | 2010-07-15 | |||
| WO2009025846A2 | 2009-02-26 | |||
| WO2015116933A2 | 2015-08-06 | |||
| WO2015048329A2 | 2015-04-02 | |||
| WO2016118629A1 | 2016-07-28 | |||
| WO2016179257A2 | 2016-11-10 | |||
| WO2016179285A1 | 2016-11-10 | |||
| WO2016179335A1 | 2016-11-10 | |||
| WO2016179003A1 | 2016-11-10 | |||
| WO2016046778A2 | 2016-03-31 | |||
| WO2016014974A2 | 2016-01-28 | |||
| WO1996002576A1 | 1996-02-01 | |||
| WO1993012227A1 | 1993-06-24 | |||
| WO1992003918A1 | 1992-03-19 | |||
| WO1994002602A1 | 1994-02-03 | |||
| WO1994025585A1 | 1994-11-10 | |||
| WO1996034096A1 | 1996-10-31 | |||
| WO1996033735A1 | 1996-10-31 | |||
| WO1992001047A1 | 1992-01-23 | |||
| WO1992020791A1 | 1992-11-26 | |||
| WO1993006213A1 | 1993-04-01 | |||
| WO1993011236A1 | 1993-06-10 | |||
| WO1993019172A1 | 1993-09-30 | |||
| WO1995001438A1 | 1995-01-12 | |||
| WO1995015388A1 | 1995-06-08 | |||
| WO2004021861A2 | 2004-03-18 |
Foreign References:
| US20160289324A1 | 2016-10-06 | |||
| US20160311903A1 | 2016-10-27 | |||
| US4816567A | 1989-03-28 | |||
| EP0239400A2 | 1987-09-30 |
Other References:
PUSKAS J. ET AL.: "Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases", IMMUNOLOGY, vol. 133, no. 2, 2011, pages 206 - 220, XP055073392, doi:10.1111/j.1365-2567.2011.03428.x
TURK B. E. ET AL.: "Determination of protease cleavage site motifs using mixture-based oriented peptide libraries", NAT. BIOTECHNOL., vol. 19, no. 7, 2001, pages 661 - 667, XP002254824, doi:10.1038/90273
ASANO RYUTARO ET AL.: "Functionalization of Bispecific Therapeutic Antibodies Based on Protein Engineering", YAKUGAKU ZASSHI, vol. 135, no. 7, 2015, pages 851 - 856, XP055600128
GERSPACH J.: "Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface", CANCER IMMUNOL. IMMUNOTHER, vol. 55, no. 12, 2006, pages 1590 - 1600, XP019422516, doi:10.1007/s00262-006-0162-6
JANICE M REICHERTCLARK J ROSENSWEIGLAURA B FADENMATTHEW C DEWITZ: "Monoclonal antibody successes in the clinic", NAT. BIOTECHNOL., vol. 23, 2005, pages 1073 - 1078, XP002555770, DOI: 10.1038/nbt0905-1073
PAVLOU AKBELSEY MJ.: "The therapeutic antibodies market to 2008", EUR. J. PHARM. BIOPHARM., vol. 59, no. 3, 2005, pages 389 - 396, XP025317626, DOI: 10.1016/j.ejpb.2004.11.007
WEINER LMSURANA RWANG S.: "Monoclonal antibodies: versatile platforms for cancer immunotherapy", NAT. REV. IMMUNOL., vol. 10, no. 5, 2010, pages 317 - 327, XP055217481, DOI: 10.1038/nri2744
GLADKOV ORAMLAU RSERWATOWSKI PMILANOWSKI JTOMECZKO JKOMAMITSKY PBKRAMER DKRZAKOWSKI MJ.: "Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer", ANTICANCER DRUGS., vol. 26, no. 10, November 2015 (2015-11-01), pages 1061 - 8
PAOLONI MMAZCKO CSELTING KLANA SBARBER LPHILLIPS JSKORUPSKI KVAIL DWILSON HBILLER B: "Defining the Pharmacodynamic Profile and Therapeutic Index ofNHS-IL12 Immunocytokine in Dogs with Malignant Melanoma", PLOS ONE, vol. 10, no. 6, 19 June 2015 (2015-06-19), pages e0129954
PAPADIA FBASSO VPATUZZO RMAURICHI ADI FLORIO AZARDI LVENTURA EGONZALEZ-IGLESIAS RLOVATO VGIOVANNONI L: "Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma", J SURG ONCOL., vol. 107, no. 2, February 2013 (2013-02-01), pages 173 - 9, XP055413902, DOI: 10.1002/jso.23168
TZENG AKWAN BHOPEL CFNAVARATNA TWITTRUP KD.: "Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution", PROC NATL ACAD SCI USA., vol. 112, no. 11, 17 March 2015 (2015-03-17), pages 3320 - 5, XP002779698
GERSPACH J1, NEMETH J, MUNKEL S, WAJANT H, PFIZENMAIER K: "Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface", CANCER IMMUNOL IMMUNOTHER., vol. 55, no. 12, December 2006 (2006-12-01), pages 1590 - 600, XP019422516, DOI: 10.1007/s00262-006-0162-6
PUSKAS JL, SKROMBOLAS D, SEDLACEK A, LORD E, SULLIVAN M, FRELINGER J: "Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases", IMMUNOLOGY., vol. 133, no. 2, June 2011 (2011-06-01), pages 206 - 20, XP055073392, DOI: 10.1111/j.1365-2567.2011.03428.x
KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492
ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 35, 2006, pages 225 - 249
PROC. NATL. ACAD. SCI. U.S.A., vol. 100, no. 11, 2003, pages 6353 - 6357
MULLBERG ET AL., J. IMMUNOL., vol. 152, no. 10, 1994, pages 4958 - 4968
NUCLEIC ACIDS RES., vol. 17, no. 8, 1989, pages 2919 - 2932
J. IMMUNOL., vol. 123, no. 4, 1979, pages 1548 - 1550
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 81, 1978, pages 1 - 7
C. EUR. J. IMMUNOL., vol. 6, no. 7, 1976, pages 511 - 519
CELL, vol. 8, no. 3, 1976, pages 405 - 415
NATURE, vol. 276, no. 5685, 1978, pages 269 - 270
J. IMMUNOL. METHODS, vol. 35, no. 1-2, 1980, pages 1 - 21
J. EXP. MED., vol. 148, no. 1, 1978, pages 313 - 323
NATURE, vol. 277, no. 5692, 1979, pages 131 - 133
KOHLERMILSTEIN ET AL., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
VANDAMME ET AL., EUR. J. BIOCHEM., vol. 192, no. 3, 1990, pages 767 - 775
BIOCHEMISTRY, vol. 18, no. 24, 1979, pages 5294 - 5299
ANAL. BIOCHEM., vol. 162, no. 1, 1987, pages 156 - 159
PROC. NATL. ACAD. SCI. USA, vol. 85, no. 23, 1988, pages 8998 - 9002
KINDT ET AL.: "Kuby Immunology", 2007, W.H. FREEMAN AND CO., pages: 91
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
PROC. NATL. ACAD. SCI. USA, vol. 103, no. 11, 2006, pages 4005 - 4010
METHODS ENZYMOL., vol. 323, 2000, pages 325 - 40
J INFLAMM (LOND)., vol. 7, 2010, pages 45
NAT REV IMMUNOL., vol. 6, no. 7, July 2006 (2006-07-01), pages 541 - 50
NAT REV DRUG DISCOV., vol. 13, no. 12, December 2014 (2014-12-01), pages 904 - 27
RESPIR RES., vol. 17, 4 March 2016 (2016-03-04), pages 23
DIS MODEL MECH., vol. 7, no. 2, February 2014 (2014-02-01), pages 193 - 203
BIOCHIM BIOPHYS ACTA, vol. 1824, no. 1, January 2012 (2012-01-01), pages 133 - 45
NAT REV CANCER., vol. 3, no. 7, July 2003 (2003-07-01), pages 489 - 501
PNAS, vol. 110, no. 1, 2 January 2013 (2013-01-02), pages 93 - 98
NAT REV DRUG DISCOV., vol. 9, no. 9, September 2010 (2010-09-01), pages 690 - 701
NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 661 - 667
PNAS, vol. 97, 2000, pages 7754 - 7759
BIOCHEMICAL JOURNAL, vol. 426, 2010, pages 219 - 228
BEILSTEIN, J NANOTECHNOL., vol. 7, 2016, pages 364 - 373
ROTHLISBERGER ET AL., J MOL BIOL., vol. 347, no. 4, 8 April 2005 (2005-04-08), pages 773 - 89
CLARK-LEWIS ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 16075 - 16081
BELPERIO ET AL.: "CXC Chemokines in Angiogenesis", J. LEUKOC. BIOL., vol. 68, 2000, pages 1 - 8, XP002440747
DUFOUR ET AL.: "IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking", J IMMUNOL., vol. 168, 2002, pages 3195 - 204
KIESEIER ET AL.: "Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10", BRAIN, vol. 125, 2002, pages 823 - 34
NAGASAWA, T., INT. J. HEMATOL., vol. 72, 2000, pages 408 - 11
GAZITT, Y., J. HEMATOTHER STEM CELL RES, vol. 10, 2001, pages 229 - 36
HATTORI ET AL., BLOOD, vol. 97, 2001, pages 3354 - 59
NOMURA ET AL., INT. J. CANCER, vol. 91, 2001, pages 597 - 606
MACHDRANOFF, CURR. OPIN. IMMUNOL., vol. 12, 2000, pages 571 - 75
BRUCE, L. ET AL.: "Radiolabeled Chemokine binding assays", METHODS IN MOLECULAR BIOLOGY, vol. 138, 2000, pages 129 - 134
RAPHAELE, B. ET AL.: "Calcium Mobilization", METHODS IN MOLECULAR BIOLOGY, vol. 138, 2000, pages 143 - 148
PAUL D. PONATH ET AL.: "Methods in Molecular Biology", vol. 138, 2000, HUMANA PRESS., article "Transwell Chemotaxis", pages: 113 - 120
PLOS ONE., vol. 5, no. 9, 13 September 2010 (2010-09-13), pages e12700
OKAZAKI ET AL., CURR. OPIN. IMMUNOL., vol. 14, 2002, pages 391779 - 82
BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 8
HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266
HANSEN ET AL., IMMUNOGENICS, vol. 10, 1980, pages 247 - 260
ISHIDA ET AL., EMBO J, vol. 11, 1992, pages 3887 - 95
FREEMAN ET AL., J EXP MED, vol. 192, 2000, pages 1027 - 34
LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8
CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43
DONG ET AL., NAT. MED., vol. 8, 2002, pages 787 - 9
DONG ET AL., J. MOL. MED., vol. 81, 2003, pages 281 - 7
BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 307 - 314
KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100
IWAI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 12293 - 7
BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66
NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 51
NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 22
SALAMA ET AL., J EXP MED, vol. 198, 2003, pages 71 - 78
PROKUNIAALARCON-RIQUELME, HUM MOL GENET, vol. 13, 2004, pages R143
NIELSEN ET AL., LUPUS, vol. 13, 2004, pages 510
OKAZAKI ET AL., PNAS, vol. 98, 2001, pages 13866 - 71
ANNU REV IMMUNOL., vol. 33, 2015, pages 139 - 67
STEM CELLS TRANSL MED., vol. 4, no. 1, January 2015 (2015-01-01), pages 66 - 73
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
N. BIOTECHNOL., vol. 28, no. 5, 2011, pages 253 - 457
MOL CELL BIOL., vol. 8, 1988, pages 466 - 472
"Current protocols in Molecular Biology", 1987, PUBLISH. JOHN WILEY & SONS
EXPERT OPIN INVESTIG DRUGS., vol. 18, no. 7, July 2009 (2009-07-01), pages 991 - 1000
CURR OPIN IMMUNOL., vol. 40, June 2016 (2016-06-01), pages 96 - 102
NATURE IMMUNOLOGY, vol. 9, 2008, pages 949 - 952
NAT CELL BIOL., vol. 18, no. 1, January 2016 (2016-01-01), pages 43 - 53
NATURE, vol. 344, 12 April 1990 (1990-04-12), pages 667 - 670
MABS., vol. 6, no. 1, January 2014 (2014-01-01), pages 204 - 18
See also references of EP 3719036A4
TURK B. E. ET AL.: "Determination of protease cleavage site motifs using mixture-based oriented peptide libraries", NAT. BIOTECHNOL., vol. 19, no. 7, 2001, pages 661 - 667, XP002254824, doi:10.1038/90273
ASANO RYUTARO ET AL.: "Functionalization of Bispecific Therapeutic Antibodies Based on Protein Engineering", YAKUGAKU ZASSHI, vol. 135, no. 7, 2015, pages 851 - 856, XP055600128
GERSPACH J.: "Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface", CANCER IMMUNOL. IMMUNOTHER, vol. 55, no. 12, 2006, pages 1590 - 1600, XP019422516, doi:10.1007/s00262-006-0162-6
JANICE M REICHERTCLARK J ROSENSWEIGLAURA B FADENMATTHEW C DEWITZ: "Monoclonal antibody successes in the clinic", NAT. BIOTECHNOL., vol. 23, 2005, pages 1073 - 1078, XP002555770, DOI: 10.1038/nbt0905-1073
PAVLOU AKBELSEY MJ.: "The therapeutic antibodies market to 2008", EUR. J. PHARM. BIOPHARM., vol. 59, no. 3, 2005, pages 389 - 396, XP025317626, DOI: 10.1016/j.ejpb.2004.11.007
WEINER LMSURANA RWANG S.: "Monoclonal antibodies: versatile platforms for cancer immunotherapy", NAT. REV. IMMUNOL., vol. 10, no. 5, 2010, pages 317 - 327, XP055217481, DOI: 10.1038/nri2744
GLADKOV ORAMLAU RSERWATOWSKI PMILANOWSKI JTOMECZKO JKOMAMITSKY PBKRAMER DKRZAKOWSKI MJ.: "Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer", ANTICANCER DRUGS., vol. 26, no. 10, November 2015 (2015-11-01), pages 1061 - 8
PAOLONI MMAZCKO CSELTING KLANA SBARBER LPHILLIPS JSKORUPSKI KVAIL DWILSON HBILLER B: "Defining the Pharmacodynamic Profile and Therapeutic Index ofNHS-IL12 Immunocytokine in Dogs with Malignant Melanoma", PLOS ONE, vol. 10, no. 6, 19 June 2015 (2015-06-19), pages e0129954
PAPADIA FBASSO VPATUZZO RMAURICHI ADI FLORIO AZARDI LVENTURA EGONZALEZ-IGLESIAS RLOVATO VGIOVANNONI L: "Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma", J SURG ONCOL., vol. 107, no. 2, February 2013 (2013-02-01), pages 173 - 9, XP055413902, DOI: 10.1002/jso.23168
TZENG AKWAN BHOPEL CFNAVARATNA TWITTRUP KD.: "Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution", PROC NATL ACAD SCI USA., vol. 112, no. 11, 17 March 2015 (2015-03-17), pages 3320 - 5, XP002779698
GERSPACH J1, NEMETH J, MUNKEL S, WAJANT H, PFIZENMAIER K: "Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface", CANCER IMMUNOL IMMUNOTHER., vol. 55, no. 12, December 2006 (2006-12-01), pages 1590 - 600, XP019422516, DOI: 10.1007/s00262-006-0162-6
PUSKAS JL, SKROMBOLAS D, SEDLACEK A, LORD E, SULLIVAN M, FRELINGER J: "Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases", IMMUNOLOGY., vol. 133, no. 2, June 2011 (2011-06-01), pages 206 - 20, XP055073392, DOI: 10.1111/j.1365-2567.2011.03428.x
KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492
ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 35, 2006, pages 225 - 249
PROC. NATL. ACAD. SCI. U.S.A., vol. 100, no. 11, 2003, pages 6353 - 6357
MULLBERG ET AL., J. IMMUNOL., vol. 152, no. 10, 1994, pages 4958 - 4968
NUCLEIC ACIDS RES., vol. 17, no. 8, 1989, pages 2919 - 2932
J. IMMUNOL., vol. 123, no. 4, 1979, pages 1548 - 1550
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 81, 1978, pages 1 - 7
C. EUR. J. IMMUNOL., vol. 6, no. 7, 1976, pages 511 - 519
CELL, vol. 8, no. 3, 1976, pages 405 - 415
NATURE, vol. 276, no. 5685, 1978, pages 269 - 270
J. IMMUNOL. METHODS, vol. 35, no. 1-2, 1980, pages 1 - 21
J. EXP. MED., vol. 148, no. 1, 1978, pages 313 - 323
NATURE, vol. 277, no. 5692, 1979, pages 131 - 133
KOHLERMILSTEIN ET AL., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
VANDAMME ET AL., EUR. J. BIOCHEM., vol. 192, no. 3, 1990, pages 767 - 775
BIOCHEMISTRY, vol. 18, no. 24, 1979, pages 5294 - 5299
ANAL. BIOCHEM., vol. 162, no. 1, 1987, pages 156 - 159
PROC. NATL. ACAD. SCI. USA, vol. 85, no. 23, 1988, pages 8998 - 9002
KINDT ET AL.: "Kuby Immunology", 2007, W.H. FREEMAN AND CO., pages: 91
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
PROC. NATL. ACAD. SCI. USA, vol. 103, no. 11, 2006, pages 4005 - 4010
METHODS ENZYMOL., vol. 323, 2000, pages 325 - 40
J INFLAMM (LOND)., vol. 7, 2010, pages 45
NAT REV IMMUNOL., vol. 6, no. 7, July 2006 (2006-07-01), pages 541 - 50
NAT REV DRUG DISCOV., vol. 13, no. 12, December 2014 (2014-12-01), pages 904 - 27
RESPIR RES., vol. 17, 4 March 2016 (2016-03-04), pages 23
DIS MODEL MECH., vol. 7, no. 2, February 2014 (2014-02-01), pages 193 - 203
BIOCHIM BIOPHYS ACTA, vol. 1824, no. 1, January 2012 (2012-01-01), pages 133 - 45
NAT REV CANCER., vol. 3, no. 7, July 2003 (2003-07-01), pages 489 - 501
PNAS, vol. 110, no. 1, 2 January 2013 (2013-01-02), pages 93 - 98
NAT REV DRUG DISCOV., vol. 9, no. 9, September 2010 (2010-09-01), pages 690 - 701
NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 661 - 667
PNAS, vol. 97, 2000, pages 7754 - 7759
BIOCHEMICAL JOURNAL, vol. 426, 2010, pages 219 - 228
BEILSTEIN, J NANOTECHNOL., vol. 7, 2016, pages 364 - 373
ROTHLISBERGER ET AL., J MOL BIOL., vol. 347, no. 4, 8 April 2005 (2005-04-08), pages 773 - 89
CLARK-LEWIS ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 16075 - 16081
BELPERIO ET AL.: "CXC Chemokines in Angiogenesis", J. LEUKOC. BIOL., vol. 68, 2000, pages 1 - 8, XP002440747
DUFOUR ET AL.: "IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking", J IMMUNOL., vol. 168, 2002, pages 3195 - 204
KIESEIER ET AL.: "Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10", BRAIN, vol. 125, 2002, pages 823 - 34
NAGASAWA, T., INT. J. HEMATOL., vol. 72, 2000, pages 408 - 11
GAZITT, Y., J. HEMATOTHER STEM CELL RES, vol. 10, 2001, pages 229 - 36
HATTORI ET AL., BLOOD, vol. 97, 2001, pages 3354 - 59
NOMURA ET AL., INT. J. CANCER, vol. 91, 2001, pages 597 - 606
MACHDRANOFF, CURR. OPIN. IMMUNOL., vol. 12, 2000, pages 571 - 75
BRUCE, L. ET AL.: "Radiolabeled Chemokine binding assays", METHODS IN MOLECULAR BIOLOGY, vol. 138, 2000, pages 129 - 134
RAPHAELE, B. ET AL.: "Calcium Mobilization", METHODS IN MOLECULAR BIOLOGY, vol. 138, 2000, pages 143 - 148
PAUL D. PONATH ET AL.: "Methods in Molecular Biology", vol. 138, 2000, HUMANA PRESS., article "Transwell Chemotaxis", pages: 113 - 120
PLOS ONE., vol. 5, no. 9, 13 September 2010 (2010-09-13), pages e12700
OKAZAKI ET AL., CURR. OPIN. IMMUNOL., vol. 14, 2002, pages 391779 - 82
BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 8
HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266
HANSEN ET AL., IMMUNOGENICS, vol. 10, 1980, pages 247 - 260
ISHIDA ET AL., EMBO J, vol. 11, 1992, pages 3887 - 95
FREEMAN ET AL., J EXP MED, vol. 192, 2000, pages 1027 - 34
LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8
CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43
DONG ET AL., NAT. MED., vol. 8, 2002, pages 787 - 9
DONG ET AL., J. MOL. MED., vol. 81, 2003, pages 281 - 7
BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 307 - 314
KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100
IWAI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 12293 - 7
BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66
NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 51
NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 22
SALAMA ET AL., J EXP MED, vol. 198, 2003, pages 71 - 78
PROKUNIAALARCON-RIQUELME, HUM MOL GENET, vol. 13, 2004, pages R143
NIELSEN ET AL., LUPUS, vol. 13, 2004, pages 510
OKAZAKI ET AL., PNAS, vol. 98, 2001, pages 13866 - 71
ANNU REV IMMUNOL., vol. 33, 2015, pages 139 - 67
STEM CELLS TRANSL MED., vol. 4, no. 1, January 2015 (2015-01-01), pages 66 - 73
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
N. BIOTECHNOL., vol. 28, no. 5, 2011, pages 253 - 457
MOL CELL BIOL., vol. 8, 1988, pages 466 - 472
"Current protocols in Molecular Biology", 1987, PUBLISH. JOHN WILEY & SONS
EXPERT OPIN INVESTIG DRUGS., vol. 18, no. 7, July 2009 (2009-07-01), pages 991 - 1000
CURR OPIN IMMUNOL., vol. 40, June 2016 (2016-06-01), pages 96 - 102
NATURE IMMUNOLOGY, vol. 9, 2008, pages 949 - 952
NAT CELL BIOL., vol. 18, no. 1, January 2016 (2016-01-01), pages 43 - 53
NATURE, vol. 344, 12 April 1990 (1990-04-12), pages 667 - 670
MABS., vol. 6, no. 1, January 2014 (2014-01-01), pages 204 - 18
See also references of EP 3719036A4
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF:
Previous Patent: EJECTION-MATERIAL EJECTION APPARATUS AND IMPRINTING APPARATUS
Next Patent: NOVEL MICROALGAE AND USE FOR SAME
Next Patent: NOVEL MICROALGAE AND USE FOR SAME